Cencora Q3 FY2026: revenue $84.75B, adjusted EPS $4.48, outlook raised
Cencora beat the $4.3924 consensus adjusted EPS estimate with $4.48 and nudged full-year guidance up to $17.75–$17.95, so the quarter reads Bullish. The catch is mix: revenue rose 5.1% to $84.75 billion while $95.74 of every $100 of revenue still goes straight to product cost. OneOncology lifted gross margin and also added debt.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS was $3.94, up 11.9% from $3.52, and adjusted EPS was $4.48 against a $4.3924 consensus — a beat of about $0.09. Gross margin at 4.26% rose 66 basis points, helped by the February 2026 OneOncology acquisition. But the GAAP line leaned on a $94.3 million LIFO credit and a $102.0 million opioid liability reduction.
Revenue came in at $84.75 billion, up 5.1% from $80.66 billion a year earlier. U.S. Healthcare Solutions, which is 88.3% of the top line, grew 4.9% to $74.86 billion, and International grew 5.9% to $7.68 billion. Growth was partly offset by lower sales to a large mail order customer and the 2025 loss of an oncology customer, both named in the filing.
Log in to read 5 analyses a week for free
Create a free account to read 5 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.